Men with non-metastatic castrate-resistant prostate cancer and rising PSA levels quickly is a medical dilemma. Rising PSA (antigen prostate) indicates that there is a cancer activity, but there are no visible metastases during scanning.
Such patients taking hormonal drugs to reduce testosterone - the hormone that feeds the cancer, but over time their cancer becomes resistant to treatment. Until recently there was no effective therapy that can improve their clinical outcomes.
For information on how to conduct an effective treatment for prostate cancer in Israel, the best specialists of the country, leave a request and we will contact you shortly.
The new double-blind, randomized Phase II study shows that a drug used to treat people with metastatic advanced cancer of the prostate, reduces the risk of metastasis and death in men with non-metastatic castrate-resistant prostate cancer and elevated PSA.
Patients who took the drug enzalutamid, had a 71% lower risk of metastasis or death compared with those who took a placebo for three years. The medicine could also prolong the duration of life without recurrence for almost two years.
"Medicine is not only reduced the spread of cancer, but improved other aspects of the disease" - the scientists noted.
In particular, the drug reduced the level of PSA in patients and the need for additional anti-cancer drugs, without reducing the quality of life.
Perhaps in the near future, the Office for sanitary inspection by the Food and Drug Administration approved enzalutamid for the treatment of men with non-metastatic castrate-resistant prostate cancer.
Prostate cancer is powered by testosterone. Enzalutamid aimed at the androgen receptor of cancer cells, resembling a tiny landing strip for the male hormones. He blocks it, causing the cells to starve. As a result, some tumor cells die, some go into dormantnoe (sleeping) state.